0RU5 Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 9.90 |
| 52 Week High | NOK 34.60 |
| 52 Week Low | NOK 5.65 |
| Beta | 1.64 |
| 11 Month Change | 11.92% |
| 3 Month Change | -15.37% |
| 1 Year Change | -37.33% |
| 33 Year Change | -99.48% |
| 5 Year Change | n/a |
| Change since IPO | -99.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RU5 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 44.5% | 1.5% | 2.2% |
| 1Y | -37.3% | -17.9% | 8.8% |
Return vs Industry: 0RU5 underperformed the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0RU5 underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| 0RU5 volatility | |
|---|---|
| 0RU5 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RU5's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0RU5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 15 | Martin Olin | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.
BerGenBio ASA Fundamentals Summary
| 0RU5 fundamental statistics | |
|---|---|
| Market cap | NOK 390.05m |
| Earnings (TTM) | -NOK 152.29m |
| Revenue (TTM) | NOK 521.00k |
748.7x
P/S Ratio-2.6x
P/E RatioIs 0RU5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RU5 income statement (TTM) | |
|---|---|
| Revenue | NOK 521.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 521.00k |
| Other Expenses | NOK 152.81m |
| Earnings | -NOK 152.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | -3.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29,230.13% |
| Debt/Equity Ratio | 0% |
How did 0RU5 perform over the long term?
See historical performance and comparison